Bancroft W H, Top F H, Eckels K H, Anderson J H, McCown J M, Russell P K
Infect Immun. 1981 Feb;31(2):698-703. doi: 10.1128/iai.31.2.698-703.1981.
Six male volunteers, previously immunized with yellow fever vaccine, were inoculated subcutaneously with a live, attenuated dengue-2 virus (PR-159/S-1) candidate vaccine. Five recipients developed viremia 8 or 9 days after vaccination, which lasted 1 to 10 days. The onset of viremia was followed by fever in three people, transient leukopenia in four, and an erythematous rash in one. One volunteer developed an oral temperature of 38.8 degrees C with headache, myalgia, fatigue, and photophobia suggestive of mild dengue fever. All five viremic volunteers developed fourfold or greater rises in serum neutralizing antibody. The sixth volunteer, who had a low titer of preexisting dengue-2 neutralizing antibody, had no viremia, no symptoms, and a modest rise in hemagglutination inhibiting antibody. Virus isolates obtained from plasma retained the small-plaque and temperature-sensitive growth characteristics of the vaccine virus in vitro. In this study, the vaccine virus genetically stable and immunogenic and seemed sufficiently attenuated for additional testing in humans.
六名曾接种过黄热病疫苗的男性志愿者皮下接种了一种减毒活登革2型病毒（PR - 159/S - 1）候选疫苗。五名接种者在接种疫苗8或9天后出现病毒血症，持续1至10天。病毒血症出现后，三人发烧，四人出现短暂性白细胞减少，一人出现红斑疹。一名志愿者体温达到38.8摄氏度，伴有头痛、肌痛、疲劳和畏光，提示为轻度登革热。所有五名出现病毒血症的志愿者血清中和抗体均有四倍或更高幅度的升高。第六名志愿者，其预先存在的登革2型中和抗体滴度较低，未出现病毒血症，没有症状，血凝抑制抗体有适度升高。从血浆中分离出的病毒在体外保留了疫苗病毒的小蚀斑和温度敏感生长特性。在本研究中，该疫苗病毒遗传稳定且具有免疫原性，似乎已充分减毒，可用于在人体中进行进一步测试。
